Roberta Zappasodi

I am investigating how co-stimulation, with agonist anti-GITR, and checkpoint blockade, with antagonist anti-CTLA4 monoclonal antibodies affect suppressive T cells in tumor microenvironment. In particular, I am involved in the study of the mechanisms of action responsible for the success or failure of these antibodies in preclinical mouse models. In addition, I am also investigating the induction of immune responses to self-antigens using a vaccine based on Alphavirus-like replicon particles (VRP) alone or in combination with immune modulation.

A New Mechanism Of Immune Regulation That Limits The Efficacy Of Immunotherapy

Immunotherapy with checkpoint blockade has revolutionized cancer treatment in the last decade. With the initial FDA approval of CTLA-4 blockade with ipilimumab in 2011 followed by the first FDA approval of PD-1 blockade with pembrolizumab in 2014, these drugs have […]